(VIANEWS) – The NYSE opens in less than three hours and Teva Pharmaceutical‘s pre-market value is already 4.38% up.
Teva Pharmaceutical’s last close was $9.82, 13.4% under its 52-week high of $11.34.
The last session, NYSE finished with Teva Pharmaceutical (TEVA) dropping 1.01% to $9.82. NYSE dropped 0.67% to $15,828.60, after two sequential sessions in a row of losses, on what was a somewhat negative trend exchanging session.
About Teva Pharmaceutical
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, it focuses on the central nervous system, pain, respiratory, and oncology areas. Its products in the central nervous system include Copaxone for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. The company's products in the respiratory market comprise ProAir, QVAR, ProAir Digihaler, AirDuo Digihaler, and ArmonAir Digihaler, BRALTUS, CINQAIR/CINQAERO, DuoResp Spiromax, and AirDuo RespiClick/ArmonAir RespiClick for the treatment of asthma and chronic obstructive pulmonary disease. Its products in the oncology market include Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim. Teva Pharmaceutical Industries Limited has a collaboration MedinCell for the development and commercialization of multiple long-acting injectable products, a risperidone suspension for the treatment of patients with schizophrenia. The company was founded in 1901 and is headquartered in Tel Aviv-Yafo, Israel.
Earnings Per Share
As for profitability, Teva Pharmaceutical has a trailing twelve months EPS of $-3.63.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -10.03%.
Sales Growth
Teva Pharmaceutical’s sales growth for the next quarter is negative 1.7%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter is 5.1% and a drop 7.8% for the next.
Volume
Today’s last reported volume for Teva Pharmaceutical is 10335258 which is 5.78% below its average volume of 9460880.
Yearly Top and Bottom Value
Teva Pharmaceutical’s stock is valued at $9.82 at 07:08 EST, way under its 52-week high of $11.34 and way above its 52-week low of $6.78.
More news about Teva Pharmaceutical (TEVA).
